ライフサイエンスコーパス: lymphangioleiomyomatosis

1 uberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis.

2 factor VEGF-D are elevated significantly in lymphangioleiomyomatosis.

3 uberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis.

4 with tuberous sclerosis complex and sporadic lymphangioleiomyomatosis.

5 e individuals to both tuberous sclerosis and lymphangioleiomyomatosis.

6 sorders tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis.

7 h the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.

8 F-D dysregulation and its cellular origin in lymphangioleiomyomatosis.

9 h the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.

10 ut not in normal volunteers or patients with lymphangioleiomyomatosis.

11 rapy for the treatment of angiomyolipoma and lymphangioleiomyomatosis.

12 regulated in TSC-related angiomyolipomas and lymphangioleiomyomatosis.

13 an immunodeficient mouse xenograft model of lymphangioleiomyomatosis.

14 l manifestations of TSC, including pulmonary lymphangioleiomyomatosis.

15 hangioleiomyomas are common in patients with lymphangioleiomyomatosis.

16 ties are seen in a majority of patients with lymphangioleiomyomatosis.

17 The antibody HMB45 is used to diagnose lymphangioleiomyomatosis, a hyperproliferative disorder

18 associated closely with the pathogenesis of lymphangioleiomyomatosis, a rare and progressive neoplas

19 Human renal angiomyolipomas and lymphangioleiomyomatosis also express markers of EMT and

20 Pulmonary lymphangioleiomyomatosis and abdominal angiomyolipoma ar

21 eptor, and progesterone receptor, similar to lymphangioleiomyomatosis and angiomyolipoma.

22 The patient also had lymphangioleiomyomatosis and lesions in the brain, skin,

23 Although lymphangioleiomyomatosis and pulmonary Langerhans cell h

24 interstitial lung diseases, with a focus on lymphangioleiomyomatosis and pulmonary Langerhans cell h

25 y that was enriched for those with pulmonary lymphangioleiomyomatosis, and was therefore composed mos

26 h the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis are associated with mutations i

27 ly always present in patients with pulmonary lymphangioleiomyomatosis, but the mechanisms underlying

28 plore the feasibility of targeting tumors in lymphangioleiomyomatosis by melanoma immunotherapy, we t

29 ma as well as the susceptibility of cultured lymphangioleiomyomatosis cells to melanoma reactive cyto

30 onse to HLA-matched melanocytes and cultured lymphangioleiomyomatosis cells.

31 yomatosis with serum levels in patients with lymphangioleiomyomatosis correlating with impaired lung

32 Our results illuminate the basis for lymphangioleiomyomatosis growth and demonstrate the ther

33 Some patients with lymphangioleiomyomatosis had improvement in spirometric

34 of clinical characteristics of subjects with lymphangioleiomyomatosis have been based on a limited nu

35 Pulmonary lymphangioleiomyomatosis is a progressive cystic lung di

36 age range of women afflicted with pulmonary lymphangioleiomyomatosis is broader than previously appr

37 and neural stem-like cell characteristics of lymphangioleiomyomatosis (LAM) and angiomyolipoma cells.

38 Lymphangioleiomyomatosis (LAM) and multifocal micronodul

39 Tumors that develop in lymphangioleiomyomatosis (LAM) as a consequence of biall

40 involved in the growth and proliferation of lymphangioleiomyomatosis (LAM) cells, abnormal smooth mu

41 (TSC) and in the differentiation of TSC with lymphangioleiomyomatosis (LAM) from sporadic LAM.

42 The true prevalence of pulmonary lymphangioleiomyomatosis (LAM) in patients with tuberous

43 Lymphangioleiomyomatosis (LAM) is a destructive lung dis

44 Lymphangioleiomyomatosis (LAM) is a disorder that affect

45 Lymphangioleiomyomatosis (LAM) is a fatal lung disease a

46 Lymphangioleiomyomatosis (LAM) is a multisystem disorder

47 Lymphangioleiomyomatosis (LAM) is a potentially fatal lu

48 Lymphangioleiomyomatosis (LAM) is a progressive and ofte

49 Lymphangioleiomyomatosis (LAM) is a progressive cystic l

50 Lymphangioleiomyomatosis (LAM) is a progressive destruct

51 Lymphangioleiomyomatosis (LAM) is a progressive disease

52 Lymphangioleiomyomatosis (LAM) is a progressive neoplast

53 Lymphangioleiomyomatosis (LAM) is a progressive, cystic

54 Lymphangioleiomyomatosis (LAM) is a rare cystic lung dis

55 Lymphangioleiomyomatosis (LAM) is a rare disease in whic

56 Lymphangioleiomyomatosis (LAM) is a rare disease that oc

57 Lymphangioleiomyomatosis (LAM) is a rare disease, occurr

58 Lymphangioleiomyomatosis (LAM) is a rare progressive lun

59 Lymphangioleiomyomatosis (LAM) is a rare, low-grade, met

60 Lymphangioleiomyomatosis (LAM) is an interstitial lung d

61 Lymphangioleiomyomatosis (LAM) is an often fatal disease

62 Pulmonary lymphangioleiomyomatosis (LAM) is an uncommon disease re

63 Lymphangioleiomyomatosis (LAM) is characterized by cysti

64 Lymphangioleiomyomatosis (LAM) is characterized by exerc

65 were made on lung tissue from 10 women with lymphangioleiomyomatosis (LAM) to evaluate the distribut

66 e diagnosis and pharmacological treatment of lymphangioleiomyomatosis (LAM) were recently published.

67 Lymphangioleiomyomatosis (LAM), a cystic lung disease as

68 Lymphangioleiomyomatosis (LAM), a disease that occurs pr

69 Lymphangioleiomyomatosis (LAM), a disorder affecting wom

70 Lymphangioleiomyomatosis (LAM), a multisystem disease of

71 Lymphangioleiomyomatosis (LAM), a rare multisystem disea

72 Lymphangioleiomyomatosis (LAM), a rare pulmonary disorde

73 ECM in diseases such as atherosclerosis and lymphangioleiomyomatosis (LAM), both characterized by ex

74 notably renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM), emerge later, placing ad

75 TSC1 or TSC2, linked to a rare lung disease, lymphangioleiomyomatosis (LAM), manifests as neoplastic

76 yolipoma (AML) is a tumor closely related to lymphangioleiomyomatosis (LAM).

77 in tuberous sclerosis (TS) and in pulmonary lymphangioleiomyomatosis (LAM).

78 SC2 function is observed in TSC and sporadic lymphangioleiomyomatosis (LAM).

79 uberin, result in the development of TSC and lymphangioleiomyomatosis (LAM).

80 loss of their function is a cause of TSC and lymphangioleiomyomatosis (LAM).

81 ene are associated with tumor development in lymphangioleiomyomatosis (LAM).

82 k of idiopathic pulmonary fibrosis (IPF) and lymphangioleiomyomatosis (LAM).

83 oliferation of abnormal smooth muscle cells (lymphangioleiomyomatosis [LAM] cells) in LAM, we perform

84 efore, boosting immune responses to gp100 in lymphangioleiomyomatosis may offer a highly desirable tr

85 table gp100 expression; thus, tumor cells in lymphangioleiomyomatosis may process melanosomal antigen

86 sociated mouse kidney tumors, and human lung lymphangioleiomyomatosis nodules.

87 2-deficient cells and pulmonary nodules from lymphangioleiomyomatosis patients contributes to tumor g

88 In clinical isolates of PBMCs from lymphangioleiomyomatosis patients, VEGF-D expression was

89 tumor-promoting roles in the pathogenesis of lymphangioleiomyomatosis, perhaps acting as both autocri

90 od of sirolimus therapy, among patients with lymphangioleiomyomatosis, the mean forced expiratory vol

91 compared with melanoma, cells cultured from lymphangioleiomyomatosis tissue were susceptible to cyto

92 One hundred twenty-eight patients with lymphangioleiomyomatosis underwent chest and abdominopel

93 om 1998 to 2001, 243 subjects with pulmonary lymphangioleiomyomatosis were enrolled into a national r

94 diagnosis of tuberous sclerosis or sporadic lymphangioleiomyomatosis were randomly assigned, in a 2:

95 Women with tuberous sclerosis-related lymphangioleiomyomatosis were younger and had less impai

96 SC-related skin tumors, angiomyolipomas, and lymphangioleiomyomatosis with serum levels in patients w